导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.99% | 2988/4773 |
| 近一周 | -2.10% | 2347/5458 |
| 近一月 | -3.51% | 2162/5421 |
| 近一季 | -8.12% | 3700/5205 |
| 近半年 | -8.92% | 3483/4920 |
| 近一年 | 0.40% | 2715/4361 |
| 近两年 | 64.23% | 1118/2954 |
| 近三年 | 18.85% | 1515/2253 |
| 成立以来 | 71.76% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.49% 1824/4961 |
14.79% 1761/5312 |
- - |
- - |
| 2025 | 27.04% 1585/4813 |
4.23% 976/3635 |
2.78% 1360/4076 |
18.07% 2355/4524 |
0.44% 1996/4813 |
| 2024 | -1.85% 2177/3463 |
-10.92% 2396/2808 |
-8.31% 2211/3014 |
15.65% 1663/3129 |
3.91% 754/3463 |
| 2023 | -5.36% 732/2656 |
8.91% 438/2280 |
-3.28% 762/2385 |
-7.47% 1579/2515 |
-2.90% 555/2655 |
| 2022 | -20.88% 998/2207 |
-14.76% 994/1919 |
3.74% 1100/2016 |
-11.49% 537/2113 |
1.08% 1392/2208 |
| 2021 | 20.74% 176/1822 |
-5.01% 902/1255 |
12.51% 328/1330 |
4.47% 348/1466 |
8.14% 162/1822 |
| 2020 | 20.45% 717/1250 |
-1.69% 229/1028 |
16.88% 405/1067 |
4.72% 945/1164 |
0.11% 1062/1184 |
| 2019 | 24.44% 617/1092 |
29.19% 284/739 |
-8.22% 584/788 |
-0.73% 612/850 |
5.72% 685/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 广发中证1000ETF联接A VS. 长安沪深300非周期A(740101) |